Sequential 5-Aza-2-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1

Todd S. Weiser, Z. Sheng Guo, Maria R. Fischette, Xiaodan Yu, G. Aaron Chen, Julie A. Hong, John H. Stewart, Dao M. Nguyen, David S. Schrump, Galen A. Ohnmacht, Maria L. Parkhurst, Panida Tong-On, Francesco M. Marincola, Steven A. Rosenberg

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)93
Number of pages1
JournalJournal of Immunotherapy
Volume24
Issue number2
StatePublished - 2001
Externally publishedYes

Keywords

  • 5-Aza-2′-deoxycytidine
  • Apoptosis
  • Depsipeptide FR901228
  • Esophageal cancer
  • Gene induction
  • Lung cancer
  • Malignant pleural mesothelioma
  • Melanoma
  • NY-ESO-1
  • Tumor immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Weiser, T. S., Guo, Z. S., Fischette, M. R., Yu, X., Chen, G. A., Hong, J. A., Stewart, J. H., Nguyen, D. M., Schrump, D. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., & Rosenberg, S. A. (2001). Sequential 5-Aza-2-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1. Journal of Immunotherapy, 24(2), 93.